Free medical quiz
Hyperlipidaemias Quiz
Focused SBA-style practice, followed by the answer and explanation for every question.
- Free now
- 5 questions
- Full bank
- 100 questions
- Answers
- Explained
Free question
Try one with the answer
A question from this quiz. Answer it to see the explanation students get.
Which of the following best describes the main mechanism of action of fibrates in the treatment of dyslipidaemia?
- A Inhibition of HMG-CoA reductase leading to reduced hepatic cholesterol synthesis You picked ✕
- B Activation of PPAR-alpha, increasing lipoprotein lipase expression You picked ✓
- C Inhibition of PCSK9 resulting in increased LDL receptor recycling You picked ✕
- D Inhibition of intestinal cholesterol absorption via blockade of NPC1L1 transporters You picked ✕
- E Sequestration of bile acids in the intestine to increase cholesterol excretion You picked ✕
Correct!
Incorrect
The answer is B: Activation of PPAR-alpha, increasing lipoprotein lipase expression
Explanation
Why B is correct
See Fibrates. Option B is correct because fibrates such as fenofibrate and bezafibrate activate PPAR-alpha (peroxisome proliferator-activated receptor alpha), a nuclear transcription factor, meaning a protein inside the cell that switches genes on. Activating it increases the production of lipoprotein lipase, the enzyme on the walls of blood vessels that breaks down triglycerides in lipoproteins, and increases uptake of fatty acids in the liver. The main result is a fall in triglycerides of about 30 to 50 per cent, with HDL often rising. The LDL response depends on the lipid pattern, and LDL can even rise in some patients with high triglycerides. The BNF states that fibrates act by decreasing serum triglycerides and have a variable effect on LDL cholesterol. They are mainly used for severe hypertriglyceridaemia, where the risk of acute pancreatitis is high, and are usually started by a specialist. Combination with a statin raises the risk of muscle damage (rhabdomyolysis), and gemfibrozil with a statin is contraindicated. A simple memory aid is that fibrates are for fats in the form of triglycerides, statins are for LDL.
- Target: PPAR-alpha, a nuclear transcription factor.
- Action: more lipoprotein lipase, the enzyme that breaks down triglycerides in lipoproteins.
- Main effect: triglycerides fall by about 30 to 50 per cent, with a variable effect on LDL.
Fibrates act through a nuclear receptor and mainly lower triglycerides, which separates them from the other four.
Why the other options are incorrect
- A. Inhibition of HMG-CoA reductase leading to reduced hepatic cholesterol synthesis: Inhibition of HMG-CoA reductase is the mechanism of statins, which mainly lower LDL cholesterol. Fibrates do not act on this enzyme. Your answer
- C. Inhibition of PCSK9 resulting in increased LDL receptor recycling: Inhibition of PCSK9 is the mechanism of antibodies such as evolocumab, which raise LDL receptor numbers. It is not how fibrates work. Your answer
- D. Inhibition of intestinal cholesterol absorption via blockade of NPC1L1 transporters: Blocking the NPC1L1 transporter is the mechanism of ezetimibe, which reduces absorption of cholesterol from the gut. Fibrates do not act on this transporter. Your answer
- E. Sequestration of bile acids in the intestine to increase cholesterol excretion: Sequestration of bile acids is the mechanism of resins such as colestyramine. Fibrates are not resins and they do not bind bile acids in the gut. Your answer
With Premium, questions you miss become Revision Coach flashcards, scheduled for review.
Question preview
What you will practice
More questions from this set. Start the quiz to answer them and see each explanation.
-
1
A 52-year-old woman with primary hypercholesterolaemia has taken the maximum tolerated dose of atorvastatin for 6 months. Her LDL cholesterol remains above target, and ezetimibe is added. Which of the following best describes the main mechanism by which ezetimibe lowers LDL cholesterol?
-
2
A 52-year-old woman with heterozygous familial hypercholesterolaemia has persistently high LDL cholesterol despite maximal tolerated statin therapy. Her lipid specialist adds evolocumab. Which mechanism best explains how this drug lowers LDL cholesterol?
SimpleMed+ Encyclopaedia
Key concepts in this topic
Short revision pages: the key facts, a memory aid and the exam traps for each concept.
-
Fibrates, PPARα and severe hypertriglyceridaemia
Fibrates activate PPARα, a protein that switches genes on, which raises lipoprotein lipase, the enzyme that breaks down triglycerides, and so lowers triglycerides.
-
PCSK9 inhibitors and LDL receptor recycling
PCSK9 inhibitors block PCSK9, a liver-made protein that sends LDL receptors to be destroyed, so the receptors are recycled to the cell surface and more LDL is cleared.
-
Statins and CYP3A4 interactions: clarithromycin, grapefruit and statin choice
Simvastatin and atorvastatin (statins, which lower cholesterol) are cleared by the enzyme CYP3A4, so strong inhibitors of it raise their levels and the risk of rhabdomyolysis (severe muscle breakdown).
Need wider coverage?
Explore every Pharmacology topic set, or build a tailored mixed session.
Browse subject quizzes